149 results on '"Lobello, S"'
Search Results
2. O6.3HIGH EDUCATIONAL LEVELS AS PROTECTIVE FACTOR AGAINST DRUG AND ALCOHOL CONSUMPTION
3. O4.2HARMFUL ALCOHOL CONSUMPTION IN HEALTH-WORKERS: RESULTS OF A SCREENING STUDY
4. Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy
5. DAILY INTERFERON MONOTHERAPY VERSUS DAILY INTERFERON PLUS AMANTADINE IN THE TREATMENT OF NAIVE CHRONIC HEPATITIS C PATIENTS: SHORT-TERM RESPONSE
6. ASYMPTOMATIC HCV CARRIERS: ARE INFECTION RISK FACTORS, HCV GENOTYPES, DEMOGRAPHIC CHARACTERISTICS, OTHER HEPATOTOXIC AGENTS AFFECTING THE CLINICAL OUTCOME?
7. P.04.1 BURDEN OF ALCOHOLIC LIVER DISEASE (ALD) ON HOSPITAL ADMISSION IN THE VENETO REGION (NORTHEAST ITALY). A RETROSPECTIVE STUDY BASED ON A LARGE DATABASE
8. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients
9. Colchicine in chronic hepatitis B: a pilot study
10. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring
11. Hospitality discharge for alcohol related problems in north east Italy in a sixteen-years period: Influence of new population at risk
12. OC.04.6 FROM ALFA-INTERFERON TO DAAS: IMPACT ON HOSPITALIZATION RATE FOR HCV LIVER RELATED DISEASES FROM 2000 TO 2016 IN NORTH EST ITALY
13. P.09.8 HOSPITALITY DISCHARGE FOR ALCOHOL-RELATED PROBLEMS IN NORTH EAST ITALY IN A SIXTEEN-YEARS PERIOD: INFLUENCE OF NEW POPULATION AT RISK
14. Right timing for transient elastography lead the right follow up after HCV treatment
15. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network
16. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group
17. Identification of a gene for chronic hepatitis B virus infection by genome-wide linkage analysis family-based association studies
18. Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?
19. Silybin conjugated with phosphatidilcholine and vitamin E improves liver damage in patients with NAFLD: the results of a randomized multicentre double-blind vs placebo trial
20. Preliminary results of A randomized multicentre double-blind vs placebo trial: evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease
21. Effect of Silybin in patients with chronic hepatitis: preliminary results of a multicentre randomized controlled trial vs placebo
22. Preliminary results of a multicentre randomized controlled trial with Silybin+phosphatidilcholine and vitamin E vs placebo in NASH patients
23. Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal
24. THU-083 - Hospitality discharge for alcohol related problems in north east Italy in a sixteen-years period: Influence of new population at risk
25. Intra-familial transmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino-acid variation of the core gene
26. Evidence for MCH class II-mediated immune selection pressure in HBV pre-core/core sequences
27. Intra-familial trasmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino acid variation of the core gene
28. YIS-4SOCIAL AND HEALTH INTEGRATED APPROACH TO ALCOHOL USE DISORDERS (AUDs) AND ALCOHOL ABUSE/DEPENDENCE: AN ITALIAN EXPERIENCE IN A SPECIALIST SERVICE
29. LP52 : Nonalcoholic fatty liver disease (NAFLD) as potential risk factor of cardiovascular disease and oncological disease in diabetic type 2 patients
30. PO. 15 Prevention and early diagnosis of colorectal cancer with endoscopy: What is useful?
31. P1282 A COST–CONSEQUENCE ANALYSIS OF SCREENING AND TREATMENT FOR CHRONIC HEPATITIS B (CHB) VIRUS INFECTION IN RESIDENT IMMIGRANTS OF AN ITALIAN NORTH-EAST REGION
32. Hepatitis B virus screening in healthy immigrants: A strategy to prevent the spread of infection and to identify and manage chronic hepatitis B (CHB)
33. Hepatitis C virus in healthy immigrants: To screen or not to screen?
34. A cost-consequence analysis of screening and treatment for chronic hepatitis B (CHB) virus infection in resident immigrants of an Italian North-East
35. Positional cloning of a novel gene associated with persistent hepatitis B virus infection
36. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial
37. Chronic hepatitis D :a vanishing disease?An Italian multicenter study
38. Colchicine in chronic hepatitis B: a pilot study
39. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring
40. O6 * FREE ORAL COMMUNICATIONS 6: PSYCHOSOCIAL FACTORS AND ALCOHOL USE DISORDERS
41. O4 * FREE ORAL COMMUNICATIONS 4: ALCOHOL INTERVENTIONS IN DIFFERENT SETTINGS
42. EPIDEMIOLOGY
43. 982 BINGE DRINKING, ALCOHOL ABUSE AND DEPENDENCE: SCREENING STUDY IN AN EMERGENCY DEPARTMENT
44. P.18.1 A PROPER ORGANIZATIONAL MODEL ENCOURAGES HIGH RATE OF INTENTION-TO-TREAT SUSTAINED VIROLOGICAL RESPONSE IN AN INJECTING DRUG USERS HCV+ POPULATION
45. 1280 NAFLD/NASH: MUCH ADO ABOUT NOTHING? A 25 YRS RETROSPECTIVE STUDY IN A COHORT OF DIABETIC PATIENTS
46. P.03.18 NAFLD/NASH: MUCH ADO ABOUT NOTHING? A 25 YRS RETROSPECTIVE STUDY IN A COHORT OF DIABETIC PATIENTS
47. Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?
48. OC8 SCREENING FOR HBV IN IMMIGRANTS: PILOT PHASE OF EPIDEMIOLOGICAL STUDY IN HEALTY POPULATION
49. 825 SILYBIN CONJUGATED WITH PHOSPHATIDYLCHOLINE AND VITAMIN E IMPROVES LIVER DAMAGE IN PATIENTS WITH NAFLD: THE RESULTS OF A RANDOMIZED MULTICENTRE DOUBLE-BLIND VS PLACEBO TRIAL
50. F-49 A randomized multicentre double-blind vs placebo trial: Evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.